Keck School of Medicine Events
Women's Cancers Program Monthly Research Seminar
"Can Antifungal Agent Be the Next Potential Therapeutic Drug For Endometrial Cancer Patients"
Tuesday, April 23, 2013
4:00 PM - 5:00 PM
Norris Topping Tower Rm. 7409
Paulette Mhawech-Fauceglia, MD, Professor of Clinical Pathology, Keck School of Medicine,will be presenting. Light refreshments will be provided.
Endometrial cancer (EC) is the most common gynecologic malignancy in developed countries. There are approximately 42,000 cases diagnosed annually in the United States., resulting in almost 8,000 deaths. Recently, glycolytic enzymes have gained considerable attention in human cancer. During cancer progression, the rapid growing tumors need rto overcome hypoxia and nutrient deprivation owing to inadequate blood supply, which leads to changes in the energy and demans of cancer cells. The metabolic changes are manefested by an increase in gluclse, fatty acid amino acid metabolism and a decrease in oxidative phosphorylation. Glucose is the primary source of energy and a high rate of glycolysis, which is the hallmark of cancer cells, provide the tumor with metabolic and survival advantages, Aldolase is an enzyme that is critical for hte glycolytic pathway, Increased aldolase expression was seen in various tumor types including cervical, endometrial, kidney and lung cancers. Our aims were to evaluate aldolase expression in endometrial carcinoma (EC) and to determine the impact of antifungal agent in inhibition of cell viability and alteration cell structure.
For more information: